SAN FRANCISCO & SHANGHAI--(BUSINESS WIRE)--Structure Therapeutics Inc. (Structure Therapeutics), formerly known as ShouTi Inc., today announced it closed an oversubscribed $33 million financing round, ...
Structure Therapeutics Inc. has announced the selection of its lead oral small molecule amylin receptor agonist, ACCG-2671, which shows promising preclinical results including potent target engagement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback